DIAGNOSTIC IMAGING: NUCLEAR MEDICINE
Since the publication of the first edition of Diagnostic Imaging: Nuclear Medicine, the world of nuclear medicine and molecular imaging has continued to rapidly evolve. PET/CT remains the most substantial advancement in the field in recent times, with PET/CT volumes continuing to climb. New PET/CT radiopharmaceuticals and time-of-flight technology have both become more mainstream. Astounding leaps have occurred in equipment such as with the incredible integrated PET/MR systems. Awareness of radiation dose to the patient has moved to the forefront of consciousness, and advances in software and detector equipment have helped dramatically lower radiation exposure. At the same time, many new therapies, radiotracers, and techniques push the boundaries of what is possible, showing the enduring importance of nuclear medicine in patient care. The second edition reflects the changes seen in practice. Careful attention has been paid to the recent revisions in radioiodine therapy guidelines for cancer and hyperthyroidism. New chapters have been added, which cover the use of Ra-223 for the treatment of painful prostate cancer bone metastases and the use of 1-123 ioflupane (DaTscan) for the diagnosis of parkinsonian syndromes. F-18 NaF PET/CT assessment for the bones is now thoroughly covered, including its indication for nonaccidental trauma in children.